TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12930428

Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical sequential bacillus Calmette‐Guérin (BCG) and epirubicin
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: BCG alone
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Epirubicin (50 or 80 mg)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Adriamycin 50 mg
Number of subjects: 533

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 533
Study: 10837439

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 9377611

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 0
Study: 8170770

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3816291

Group type: EXPERIMENTAL
Intervention: Trimoprostil 0.125 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Trimoprostil 1.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30593989

Group type: EXPERIMENTAL
Intervention: School success and peer support
Number of subjects: 768

Group type: COMPARATOR
Intervention: Threat appraisals of interparental conflict
Number of subjects: 768
Study: 29174623

Group type: EXPERIMENTAL
Intervention: Nonsurgical and noninjection therapies
Number of subjects: 125
Study: 26742872

Group type: EXPERIMENTAL
Intervention: Releasable suture technique 1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Releasable suture technique 2
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Releasable suture technique 3
Number of subjects: 90
Study: 25245413

Group type: COMPARATOR
Intervention: Normal-sized LA
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Dilated LA
Number of subjects: 5496
Study: 22001391

Group type: EXPERIMENTAL
Intervention: Tipifarnib (T) 600 mg twice a day × 14 days, Etoposide (E) 100 mg days 1‐3 and 8‐10
Number of subjects: 84

Group type: COMPARATOR
Intervention: Tipifarnib (T) 400 mg twice a day × 14 days, Etoposide (E) 200 mg days 1‐3 and 8‐10
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tipifarnib plus Etoposide in patients with a RASGRP1/APTX ratio of more than 5.2
Number of subjects: 84
Study: 19848555

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg) plus one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625 mg conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate) plus one Cal+D tablet daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (one Cal+D tablet only)
Number of subjects: 150
Study: 16928395

Group type: EXPERIMENTAL
Intervention: Targeted intervention program (seven sessions)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 15689198

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation followed by painful stimulation of the temple (ice applications)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation with painful stimulation of the temple (ice applications)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hand immersion in ice water during optokinetic stimulation
Number of subjects: 27
Study: 11891813

Group type: EXPERIMENTAL
Intervention: WinRho-SD (25 or 50 microg/kg)
Number of subjects: 7
Study: 9527081

Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin patches (0.4, 0.8, or 1.6 mg/hour)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 7608351

Group type: EXPERIMENTAL
Intervention: Scheduled reduced smoking (progressive increase in the intercigarette interval)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nonscheduled reduced smoking (gradual reduction, no specific change in the intercigarette interval)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Scheduled nonreduced smoking (fixed intercigarette interval, no reductions in frequency)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nonscheduled nonreduced smoking (no change in intercigarette interval or smoking frequency)
Number of subjects: 128
Study: 2708843

Group type: EXPERIMENTAL
Intervention: Single daily dose of netilmicin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Multiple daily doses of netilmicin
Number of subjects: 70
Study: 29493280

Group type: EXPERIMENTAL
Intervention: Educational programme for primary caregivers
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional rehabilitation alone
Number of subjects: 63
Study: 27629750

Group type: EXPERIMENTAL
Intervention: Berberine treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mere lifestyle intervention
Number of subjects: 80
Study: 26374429

Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-FU
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 1608

Group type: COMPARATOR
Intervention: No oxaliplatin
Number of subjects: 1608
Study: 24245707

Group type: EXPERIMENTAL
Intervention: Internet-based exposure treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: One-session exposure treatment (OST)
Number of subjects: 30
Study: 21042231

Group type: EXPERIMENTAL
Intervention: 3 injections of TDV at months 0, 3.5, and 12 (TDV-TDV-TDV)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 1 injection of yellow fever vaccine (YF) at month 0, and 2 injections of TDV at months 3.5 and 12 (YF-TDV-TDV)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 3 injections of TDV
Number of subjects: 126
Study: 19296144

Group type: EXPERIMENTAL
Intervention: Before-breakfast dosing of risedronate 5 mg daily
Number of subjects: 3112

Group type: COMPARATOR
Intervention: Flexible dosing of risedronate 5 mg daily (2 h before and 2 h after any food and drink other than plain water)
Number of subjects: 3112
Study: 17134335

Group type: EXPERIMENTAL
Intervention: Web administration of social desirability questionnaires
Number of subjects: 404

Group type: COMPARATOR
Intervention: Laboratory administration of social desirability questionnaires
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Self-selected online administration of social desirability questionnaires
Number of subjects: 404
Study: 12956024

Group type: EXPERIMENTAL
Intervention: Multi-intervention programme of exercise and social support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 10950818

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 11
Study: 9060551

Group type: EXPERIMENTAL
Intervention: Amoxicillin (2,250 mg) + Omeprazole for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + Omeprazole for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PCR analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: H pylori eradication
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyclonal PCR in gastritis patients
Number of subjects: 20
Study: 8154249

Group type: EXPERIMENTAL
Intervention: Topical carteolol 2%
Number of subjects: 9

Group type: COMPARATOR
Intervention: Biological salt solution (control)
Number of subjects: 9
Study: 3097668

Group type: EXPERIMENTAL
Intervention: Intra-nasal buserelin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral danazol
Number of subjects: 80
Study: 30116062

Group type: COMPARATOR
Intervention: Provincial hospitals
Number of subjects: 124
Study: 27121850

Group type: EXPERIMENTAL
Intervention: Social media exposure (Facebook and Twitter posts, boosted and retweeted); 74 manuscripts
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control (no social media exposure); 78 manuscripts
Number of subjects: 152
Study: 24621228

Group type: EXPERIMENTAL
Intervention: Active stimulation (responsive focal cortical stimulation)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 191
Study: 22534594

Group type: EXPERIMENTAL
Intervention: RIME-structured scoring format
Number of subjects: 547
Study: 20724336

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18996864

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) containing glutamine, carbohydrates, and antioxidants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glutamine infusion alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 16872926

Group type: EXPERIMENTAL
Intervention: Conventional prostheses (CP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Implant-supported prostheses (IP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Implants placed
Number of subjects: 46
Study: 14698357

Group type: EXPERIMENTAL
Intervention: Johrei
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mock neurofeedback relaxation control
Number of subjects: 48
Study: 11078457

Group type: EXPERIMENTAL
Intervention: Prolonged hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Short-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 5 min)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Day 1 euglycemia (5.2 +/‐ 0.1 mmol/l)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intermediate-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Number of subjects: 31
Study: 10165528

Group type: COMPARATOR
Intervention: Standard intravenous (i.v.) antibacterial therapy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Abbreviated regimen of intravenous antibacterials for 2 to 4 days followed by oral ciprofloxacin or oral enoxacin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Switch therapy
Number of subjects: 187
Study: 7934684

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 150 micrograms/10 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 3728446

Group type: EXPERIMENTAL
Intervention: Self-administered mailed questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone and home interview modes
Number of subjects: 0
Study: 31414370

Group type: EXPERIMENTAL
Intervention: Health education given in Arabic
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 60
Study: 30893230

Group type: EXPERIMENTAL
Intervention: No Sling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sling
Number of subjects: 80
Study: 27938990

Group type: EXPERIMENTAL
Intervention: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) once a week for 5 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham treatment once a week for 5 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) after a 4-week break, once a week for 5 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham treatment after a 4-week break, once a week for 5 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low-Energy Linear Shockwave Therapy (LLi‐ESWT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 126
Study: 25261241

Group type: EXPERIMENTAL
Intervention: Contact lens
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 23862237

Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule + Tamsulosin Hydrochloride
Number of subjects: 242

Group type: COMPARATOR
Intervention: Quinolinone antibiotics + Tamsulosin Hydrochloride
Number of subjects: 242
Study: 21493665

Group type: EXPERIMENTAL
Intervention: Overnight closed loop delivery of insulin after a medium sized evening meal (60 g of carbohydrates) at 1900.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overnight closed loop delivery of insulin after a larger evening meal (100 g of carbohydrates) at 2030, accompanied by white wine (0.75 g/kg ethanol).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pooled data analysis of overnight closed loop delivery of insulin.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overnight closed loop delivery of insulin.
Number of subjects: 24
Study: 19558835

Group type: EXPERIMENTAL
Intervention: Local and general dexamethasone administration
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone injection
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection
Number of subjects: 78

Group type: COMPARATOR
Intervention: Comparison among all groups
Number of subjects: 78
Study: 16925616

Group type: EXPERIMENTAL
Intervention: Serial Trial Intervention (STI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatments
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 57

Group type: COMPARATOR
Intervention: Not-for-profit facilities
Number of subjects: 57
Study: 15191380

Group type: EXPERIMENTAL
Intervention: Albendazole 10 mg/kg for 5 days
Number of subjects: 107

Group type: COMPARATOR
Intervention: Metronidazole 20 mg/kg daily in three doses for 7 days
Number of subjects: 107
Study: 11465638

Group type: EXPERIMENTAL
Intervention: 450 mg moclobemide during the first week, and 600 mg afterwards
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9157942

Group type: EXPERIMENTAL
Intervention: 4 g/d of eicosapentaenoic and docosahexaenoic acids (fish oil)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Corn oil placebo
Number of subjects: 78
Study: 8354983

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with beta blockers and diuretics for a mean follow-up of 25 months
Number of subjects: 1627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study: 3440385

Group type: EXPERIMENTAL
Intervention: 24 hours of oxygen administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 hours of oxygen administration
Number of subjects: 0
Study: 31578132

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30632775

Group type: EXPERIMENTAL
Intervention: HealthMpowerment (HMP) online intervention
Number of subjects: 48
Study: 27532605

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg∙kg‐1)
Number of subjects: 16
Study: 23865977

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30
Study: 22383591

Group type: EXPERIMENTAL
Intervention: Guideline-based care
Number of subjects: 523

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 523
Study: 20441132

Group type: EXPERIMENTAL
Intervention: Color-digit synesthesia (SE)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1
Study: 18395728

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 72
Study: 15825785

Group type: EXPERIMENTAL
Intervention: ibuprofen/ibuprofen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: flurbiprofen/flurbiprofen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: acetaminophen/acetaminophen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: naproxen sodium/naproxen sodium
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: aspirin/aspirin
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 150
Study: 12424402

Group type: EXPERIMENTAL
Intervention: Topical latanoprost (0.005%, once daily) for 30 days (monotherapy group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical latanoprost (0.005%, once daily) for 180 days (combination treatment group)
Number of subjects: 24
Study: 10331150

Group type: EXPERIMENTAL
Intervention: Healthy fetuses (normal pregnancies)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Growth-restricted fetuses (complicated pregnancies)
Number of subjects: 29
Study: 8951927

Group type: EXPERIMENTAL
Intervention: Lornoxicam (4, 8, 16 and 20 mg)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Morphine (10 and 20 mg)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Lornoxicam (4 mg)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Lornoxicam (all doses)
Number of subjects: 252
Study: 1657611

Group type: EXPERIMENTAL
Intervention: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at doses of 5, 10, 20, 50 and 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at 10 mg/d for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I)
Number of subjects: 0
Study: 6942835

Group type: EXPERIMENTAL
Intervention: 2 g deanol per day
Number of subjects: 33

Group type: COMPARATOR
Intervention: 1 g deanol per day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30827911

Group type: COMPARATOR
Intervention: Sleep Restriction (SR; 5‐h sleep opportunities)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Weekend Recovery (WR; insufficient sleep for 5‐day workweek, then 2 days of weekend recovery)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON; 9‐h sleep opportunities)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Weekend Recovery (WR)
Number of subjects: 36
Study: 30172435

Group type: EXPERIMENTAL
Intervention: Foster care group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Institutionalized group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Family care group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Institutionalized group boys
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Foster care group and institutionalized group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Age of menarche
Number of subjects: 165
Study: 27176660

Group type: EXPERIMENTAL
Intervention: Self-awareness intervention manipulation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 24898300

Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg weekly, uptitrated to 50 mg if necessary)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Thrice-daily prandial insulin lispro
Number of subjects: 563
Study: 22723322

Group type: EXPERIMENTAL
Intervention: Teriparatide (56.5 μg)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study: 20369761

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl 25 microg and a nitroglycerine patch (Group F-N)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bupivacaine plus fentanyl 25 microg and a placebo patch (Group F)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus saline 0.5 ml and a nitroglycerine patch (Group B-N)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bupivacaine plus saline 0.5 ml and a placebo patch (Group B)
Number of subjects: 120
Study: 17368339

Group type: EXPERIMENTAL
Intervention: sodium perborate + 30% hydrogen peroxide solution (SP + HP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sodium perborate + water (SPW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sodium perborate + 2% chlorhexidine gel (SP + CHX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide gel (CP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide gel + 2% chlorhexidine gel (CP + CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: water (W)
Number of subjects: 60
Study: 15746295

Group type: EXPERIMENTAL
Intervention: Chronic low-frequency electrical stimulation training of the tibialis anterior muscle for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12426215

Group type: EXPERIMENTAL
Intervention: Soy protein (minimum of 25 g animal protein or isolated soy protein/4.2 MJ)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Soy protein in individuals with LDL cholesterol > or =4.14 mmol/L
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Isoflavones (50 mg/4.2 MJ)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Animal protein (control group)
Number of subjects: 42
Study: 10361533

Group type: EXPERIMENTAL
Intervention: Nontailored newsletters
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Computer‐tailored newsletters
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tailored newsletters with tailored goal‐setting information
Number of subjects: 710

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 710
Study: 8534412

Group type: EXPERIMENTAL
Intervention: velnacrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eptastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CI‐979
Number of subjects: 0
Study: 2045759

Group type: EXPERIMENTAL
Intervention: High intake of vitamin-K-rich vegetables for 7 days (median daily vitamin K intake 1100 micrograms)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High intake of vitamin-K-rich vegetables for 1 day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High intake of vitamin-K-rich vegetables for 2 days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Phytomenadione supplementation (1000 micrograms daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: High intake of vitamin-K-poor vegetables for 6 days
Number of subjects: 37